Table 9.

PhAcase, POase, and neuropsychological measures of cognition at baseline and the end of study

Variable	Mean±SD at baseline		Mean±SD at the end-of-study (EOS)		p B-vit. versus placebo group#		p EOS versus baseline#
(n = 97–133)
	Placebo group	B-vitamin group	Placebo group	B-vitamin group	Baseline	EOS	Placebo group	B-vit. group
PhAcase$, units	0.481±0.132	0.497±0.143	0.448±0.121	0.468±0.117	0.400	0.246	2.E–5*	0.003*
POase, unitsX100	10.4±6.3	9.3±7.0	10.2±5.8	9.5±6.6	0.256	0.425	0.235*	0.327*
tHcy, μM	12.1±4.1	11.8±3.4	13.1±4.7	8.9±2.2	0.503	1.E–14	0.112	7.E–13
MMSE	28.2±1.5	28.1±1.8	27.7±2.3	27.8±2.2	0.750	0.626	0.029	0.224
							0.007*	0.056*
TICS-m$	25.0±2.7	24.8±2.9	26.5±4.4	26.9±5.0	0.540	0.722	0.009	0.004
							0.002*	0.003*
HVLT-TR$	23.0±5.1	23.5±5.4	22.9±5.8	23.3±6.7	0.592	0.918	0.586*	0.052*
HVLT-DR	7.4±3.2	7.7±2.9	6.9±3.6	7.4±3.5	0.241	0.303	0.046*	0.199*
Trail Making A	53.1±24.5	51.0±19.0	56.7±41.6	52.4±39.8	0.603	0.255	0.697*	0.694*
SDMT$	37.1±9.9	37.9±10.0	35.4±11.0	37.4±11.0	0.312	0.064	0.002*	0.214*
Category Fluency	19.8±5.1	20.3±4.9	19.3±5.8	20.1±4.8	0.451	0.161	0.252*	0.233*
Map Search	53.4±14.9	53.0±13.6	53.4±17.7	54.6±16.5	0.799	0.506	0.909*	0.577*

^$Normally distributed data. ^#p-values were derived from Log-transformed values: two-sided T-test except where noted; ^*paired T-test.